NHS England ECONOMIC

Target: NHS England Research date: 26 October 2026 Entity type: UK statutory public body Geographic scope: Israel, West Bank including East Jerusalem, Golan Heights, and relevant group-level supplier relationships Evidence scope: Publicly available government publications, official institutional records, corporate filings, and local-authority proceedings.

Supply Chain & Sourcing Relationships

Direct supplier relationships

NHS England awarded a contract in November 2023 for the NHS Federated Data Platform to a consortium led by Palantir Technologies UK Ltd, with an advertised maximum contract value of £330 million over a potential seven-year period, according to the contract details recorded in Manchester City Council’s September 2026 proceedings.¹

The contract concerns national healthcare data infrastructure, including software supporting patient care, hospital management, waiting-list planning, and health-service decision-making.¹

The arrangement provides a verified commercial link between NHS England and Palantir’s corporate group, which separately disclosed a 2024 strategic partnership with the Israeli Ministry of Defence to provide technology supporting Israel’s war effort.²

Palantir’s 2024 Form 10-K describes the defence partnership as an agreement to “supply technology to Israel to assist in the ongoing war”.²

The financial disclosure identifies Palantir’s Israeli defence relationship as an activity of the supplier group; it does not identify NHS England as a party to that relationship.²

Agricultural suppliers

Mehadrin, Hadiklaim, Galilee Export, Agrexco successor companies, and direct procurement of Israeli-origin dates, citrus, avocados, fresh herbs, or potatoes: no public evidence identified.

Importer-of-record structure

A wholly owned NHS England import subsidiary, Israeli sourcing joint venture, or dedicated importer of record for Israeli-origin goods: no public evidence identified.

Seasonal sourcing

Recurring December–April purchases of Israeli agricultural products attributable directly to NHS England: no public evidence identified.

Third-party and indirect sourcing

The 2023 Federated Data Platform procurement illustrates the role of external contractors in supplying NHS England with digital infrastructure; the identified contractor is Palantir Technologies UK Ltd, while the independently documented Israeli military relationship concerns the wider Palantir group.^{1, 2}

The procurement relationship does not itself establish that Israeli-manufactured goods or Israeli-developed components were supplied under the NHS contract.^{1, 2}

Specific Israeli-origin products delivered through intermediaries, distributors, white-label arrangements, or subcontractors to NHS England: no public evidence identified.

Named programmes and intermediaries

Manchester City Council’s September 2026 proceedings identify the Federated Data Platform as a nationally procured system deployed by individual NHS provider organisations, including Manchester University NHS Foundation Trust and providers in the Greater Manchester Cancer Alliance.¹

The proceedings identify diagnostic-test scheduling, patient follow-up, operating-theatre scheduling, activity planning, referral-to-treatment validation, and equipment-management applications as examples of local FDP use.¹

Specific evidence connecting these individual clinical applications to systems supplied to the Israeli Ministry of Defence: no public evidence identified.

The published NHS Federated Data Platform procurement record specifies 15 February 2027 as the end date of the initial contractual period. NHS England awarded the contract to Palantir Technologies UK Ltd on 22 November 2023, with a published initial contract value of £182,242,760. The arrangement provides for an initial three-year term followed by optional extensions of two years, one year and one year. This confirms the existing audit’s reference under “Civil-society and institutional scrutiny” to a February 2027 contractual break opportunity and clarifies the less precise “spring 2027” description in Political. The distinction matters because official departmental statements have also described the initial term as ending in March 2027. The published procurement end date supports 15 February 2027 as the more precise date, although it does not independently establish the deadline for serving contractual notice or exercising the option.^{3, 4}

Product Origin, Labeling & Regulatory Compliance

Settlement-origin products

The UK government’s August 2025 notice to importers states that products manufactured in Israeli settlements in territories brought under Israeli administration since June 1967 are ineligible for preferential treatment under the UK-Israel Trade and Partnership Agreement.⁵

The notice requires importers claiming preferential origin to consider the production location identified on relevant certificates and invoice declarations.⁵

No public evidence identified establishing that NHS England directly imported products originating in an Israeli settlement.

Labelling requirements

UK government overseas-business-risk guidance states that produce originating in Israeli settlements should be identified accordingly under the applicable country-of-origin labelling approach.⁶

The government distinguishes the occupied territories from the territory eligible for preferential treatment under the UK-Israel trade agreement.⁷

Target-specific compliance

An NHS England enforcement notice, customs penalty, regulator finding, or substantiated allegation of mislabelling settlement-origin goods: no public evidence identified.

Corporate labelling and sourcing policy

A specific NHS England policy governing the purchase or labelling of Israeli settlement-produced goods: no public evidence identified.

Medical products and healthcare procurement

NHS England is a national statutory healthcare organisation, while the consolidated NHS provider accounts separately report the finances of NHS trusts and NHS foundation trusts.⁸

Consequently, transactions undertaken by an individual hospital or trust cannot be identified as direct NHS England purchases without contractual or accounting evidence connecting that transaction to NHS England.⁸

A verified NHS England-specific procurement record for an Israeli-manufactured medical device, pharmaceutical product, or settlement-origin healthcare product: no public evidence identified.

Investment, Capital & Financial Exposure

Foreign direct investment

NHS England’s 2025–2026 annual report and accounts document its financial position as a public healthcare body accountable through the UK government’s reporting framework.⁹

The organisation’s financial structure differs from a privately owned multinational conducting shareholder-financed overseas acquisitions.⁹

NHS England-owned Israeli factories, warehouses, data centres, property assets, or incorporated operating businesses: no public evidence identified.

Acquired Israeli operating companies

No public evidence identified that NHS England acquired or owns a controlling equity interest in an Israeli manufacturer, pharmaceutical company, biotechnology company, technology enterprise, food producer, infrastructure operator, or consumer brand.

Accordingly, no verified acquisition date, purchase price, ownership percentage, Israeli factory location, workforce, revenue contribution, or defence-related subsidiary activity can be enumerated.

Research and development investment

The UK and Israel signed a bilateral science, technology, research, and innovation memorandum on 20 September 2023 through their respective government departments responsible for science and innovation.¹⁰

The named government parties were the UK’s Department for Science, Innovation and Technology and Israel’s Ministry of Innovation, Science and Technology.¹⁰

The memorandum is evidence of government-level cooperation; it does not establish an NHS England investment, operating research centre, or financial commitment under the arrangement.¹⁰

An NHS England-owned Israeli research laboratory, accelerator, technology incubator, or intellectual-property development subsidiary: no public evidence identified.

Ownership and parent-entity financial structure

NHS England was established under UK public law as a non-departmental public body responsible for NHS commissioning and related national healthcare functions.¹¹

Government financial directions for 2026–2027 establish ministerially determined budgets rather than financing through commercial equity shareholders.¹²

An Israeli private-equity sponsor, Israeli majority shareholder, Israeli beneficial owner, or Israeli state equity interest in NHS England: no public evidence identified.

Supplier-group exposure

Palantir Technologies Inc.’s 2024 Form 10-K explicitly disclosed its strategic partnership with the Israeli Ministry of Defence.²

The filing also stated that its then-current operations related to Ukraine and Israel were not material to its financial position or operating results.²

Palantir’s 2025 Form 10-K identifies Palantir Technologies Inc. as a Delaware-incorporated US company and provides the group’s subsequent annual financial-reporting context.¹³

The NHS England contract and Palantir’s Israeli defence activities represent separately documented relationships involving the same wider supplier group.^{1, 2}

A quantified transfer of NHS England contract revenue to the Israeli Ministry of Defence, or identifiable application of NHS England receipts to Palantir’s Israeli operations: no public evidence identified.

Portfolio and fund exposure

NHS England holdings in Israeli-domiciled listed equities, Israeli sovereign bonds, Israel Bonds, Israeli venture-capital funds, or Israeli defence-industry investment funds: no public evidence identified.

Financing the Israeli state

NHS England underwriting of Israeli sovereign debt, arranging Israel Bonds, direct lending to Israeli defence contractors, underwriting military insurance, or financing Israeli settlement enterprises: no public evidence identified.

Controlling principals and personal investments

The government’s official biography of Matthew Gould records that he held NHS England digital-transformation responsibilities and previously served as British Ambassador to Israel, where he established the UK-Israel Tech Hub.¹⁴

The same biography documents his diplomatic service in Israel during 2010–2015 and subsequent UK public-sector technology responsibilities.¹⁴

The biography does not establish a personal investment by Gould in an Israeli company or defence enterprise.¹⁴

A verified material Israeli company investment, family-office vehicle, settlement investment, or Israeli defence-industry equity holding attributable to NHS England’s current chair, executives, or other board members: no public evidence identified.

On 22 October 2026, the UK government confirmed that the NHS England Federated Data Platform contract with Palantir would undergo a review before a decision on exercising its optional two-year extension. The government’s published response specified that the review would follow the Cabinet Office Contract Management Playbook and assess contractual performance, service-level key performance indicators, delivery against contractual obligations, financial performance, alignment with NHS priorities and value for money. It also confirmed that the contract contains provisions supporting service continuity and transition if the extension is declined. The government did not commit to terminating the arrangement, and any decision to end or vary the contract would remain subject to its terms and public procurement law. Contemporary reporting independently confirms the government’s decision to leave the break-clause question open, although the detailed review criteria could only be checked against the parliamentary publication, whose host is excluded from citation.¹⁵

On 28 August 2026, the Department of Health and Social Care confirmed that NHS England had commissioned Imperial College London to undertake an independent evaluation of the Federated Data Platform’s impact, implementation processes and value for money. The Office for Statistics Regulation had independently confirmed the commissioning on 22 July 2026, identifying the Inpatients and OPTICA applications as evaluation priorities because their claimed benefits raised particular questions about causality. The regulator recorded NHS England’s intention to publish the evaluation findings. The commissioning establishes an independent assessment mechanism but does not itself demonstrate that the programme has achieved value for money or that its claimed operational benefits are causally attributable to the platform.¹⁶

The Department of Health and Social Care’s 28 August 2026 response also confirmed that the National Audit Office had begun examining NHS patient-data integration investments. The National Audit Office independently identifies its study, “Integrating patient records: laying the foundations for a more productive NHS”, as work in progress, examining whether DHSC and the NHS in England are on track to realise expected improvements from their investments. Its scope includes oversight of national programmes, integration of patient records and the contribution of digital infrastructure to healthcare productivity. The study encompasses national initiatives including the Federated Data Platform but is broader than an audit of Palantir’s individual contract. The NAO lists the report for winter 2026–2027; its published work-in-progress description does not establish a completed value-for-money finding concerning the FDP.^{17, 18}

The primary departmental response establishing the 28 August 2026 confirmation is the Department of Health and Social Care’s answer to House of Lords written question HL1938, submitted by Lord Scriven on 9 July 2026 and answered by Baroness Merron on 28 August 2026. The response expressly identifies Imperial College London as NHS England’s commissioned academic partner for an independent evaluation of the Federated Data Platform’s impact, implementation processes and value for money, and states that the evaluation was in progress. This confirms the substance and date of the existing audit’s 28 August statement, while identifying the departmental response separately from End Note 23, which refers to the Office for Statistics Regulation’s earlier publication of 22 July 2026. The regulator independently establishes that the evaluation had already been commissioned by July and that Inpatients and OPTICA were priority applications. The August departmental response is therefore subsequent confirmation of an existing evaluation, rather than evidence that commissioning first occurred on 28 August. The primary response was located and opened, but its parliamentary host is excluded by the audit’s citation rules; the permitted regulatory source below independently supports the commissioning and evaluation scope.¹⁶

Operational Presence & Market Activity

Physical presence

NHS England’s public institutional reporting concerns its responsibilities for healthcare delivery, oversight, digital infrastructure, and NHS financing in England.^{9, 19}

An NHS England-owned office, sales branch, warehouse, hospital, administrative centre, or registered operating establishment in Israel, East Jerusalem, the West Bank, or the Golan Heights: no public evidence identified.

Employees and taxation

The organisation’s accounts are published under the UK public-sector reporting framework rather than through Israeli corporate financial reporting.⁹

An Israeli payroll, Israeli corporate income-tax registration, Israeli VAT registration, Israeli Preferred Technology Enterprise designation, or disclosed NHS England employment headcount in Israel: no public evidence identified.

Indirect service relationships

The September 2026 Manchester City Council proceedings document the implementation of Palantir’s Federated Data Platform at certain NHS trusts and clinical organisations.¹

The same proceedings identify NHS Greater Manchester’s locally developed Analytics and Data Science Platform as a separate arrangement from the national FDP procurement.¹

These records establish UK operational deployment of a supplier’s healthcare technology, without establishing an NHS England physical operation in Israel.¹

Supplier’s Israeli operations

Palantir’s 2024 Form 10-K confirms a strategic relationship with the Israeli Ministry of Defence to provide technology for wartime activities.²

The corporate disclosure identifies a defence technology relationship; it does not identify NHS England as a customer, subcontractor, user, or operator of the Israeli defence systems.²

Israeli market positioning

An NHS England annual-report statement identifying Israel as an export market, commercial growth market, operational hub, or source of healthcare-service revenue: no public evidence identified.

Settlement operations

NHS England operation of facilities, commercial outlets, support centres, software installations, infrastructure, or revenue-producing activities in Israeli settlements: no public evidence identified.

Post-July 2024 and post-November 2024 continuity

Manchester City Council’s September 2026 proceedings confirm that the nationally procured FDP remained subject to NHS operational use and local-authority scrutiny after the July 2024 and November 2024 chronology thresholds.¹

This establishes documented continuation of the NHS supplier relationship and associated programme activity into 2026; it does not establish that NHS England itself participated in Israeli military operations.^{1, 2}

Civil-society and institutional scrutiny

The September 2026 Manchester council proceedings document opposition to Palantir’s role in NHS data infrastructure, citing its defence activities, healthcare-data privacy, procurement costs, and supplier dependency.¹

The proceedings also record calls for exercising a February 2027 contractual break clause and evaluating alternative healthcare data platforms.¹

These statements represent local political proceedings and scrutiny of the procurement, rather than a regulator’s determination that NHS England committed a financial or legal violation.¹

Corporate Structure & Foundational Ties

Founding and incorporation

The UK government described NHS England in 2013 as a non-departmental public body accountable to the Secretary of State for Health.¹¹

NHS England’s predecessor organisation was constituted under UK health legislation and exercised national NHS commissioning responsibilities.¹¹

No public evidence identified that NHS England was founded, incorporated, or originally headquartered in Israel.

Organisational history

NHS Digital’s statutory functions transferred to NHS England on 1 February 2023 under the Health and Social Care Information Centre transfer regulations.²⁰

Official NHS organisational records also identify the subsequent integration of Health Education England into the wider NHS England organisation in April 2023.²¹

These were mergers of UK public healthcare bodies, without evidence of an acquired Israeli commercial operating company.^{20, 21}

Legal domicile and headquarters

NHS England’s governance and reporting framework is established through UK healthcare legislation and UK governmental accountability arrangements.^{9, 11}

An Israeli legal domicile, Israeli registered headquarters, or dual UK-Israel corporate headquarters: no public evidence identified.

State ownership and institutional linkages

The UK government’s 2025 mandate sets objectives for NHS England under the statutory relationship with the Secretary of State for Health and Social Care.²²

The government’s 2026–2027 financial directions prescribe NHS England’s annual financial allocations within the UK public healthcare system.¹²

The proposed reorganisation announced on 13 March 2025 would abolish NHS England and transfer its functions into the Department of Health and Social Care, subject to parliamentary approval.¹⁹

As of the government’s September 2026 impact-assessment publication, that transfer remained a proposed statutory restructuring rather than an independently established completed dissolution.¹⁹

Governance structure

NHS England’s 2024–2025 annual report includes its board governance, accountability, and financial statements.²³

No public evidence identified of an Israeli government-appointed NHS England director, Israeli state golden share, Israeli shareholder voting right, or governance charter binding NHS England to Israeli government policy.

Historical individual connections

Matthew Gould’s official UK government biography records his service as British Ambassador to Israel and his role in developing the UK-Israel Tech Hub before his NHS England digital-transformation responsibilities.¹⁴

The disclosed professional background does not itself establish an NHS England corporate investment in Israel.¹⁴

Israeli-Nexus Floor indicators

• Founded in Israel: no public evidence identified.
• Israeli headquarters or principal management: no public evidence identified.
• Israeli tax residency or Preferred Technology Enterprise status: no public evidence identified.
• Beneficial ownership or control by Israeli capital: no public evidence identified.

Controlling Israeli subsidiaries

No public evidence identified.

Other group entities

The 2023 integration of NHS Digital and Health Education England represents the consolidation of UK public functions into NHS England, rather than the formation of a privately controlled international corporate group.^{20, 21}

No public evidence identified of an Israeli subsidiary, Israeli-controlled affiliate, or Israeli acquisition arising from those integrations.

Profit Repatriation & Economic Contribution

Revenue attribution

NHS England’s financial resources are governed by public-sector statutory allocations and reporting obligations.^{9, 12}

The 2025–2026 financial directions prescribed a revenue resource-use limit of £205.111 billion when originally issued in March 2025, with subsequent revised directions issued in March 2026.^{24, 25}

These amounts represent national public healthcare financial allocations and do not establish commercial sales to Israel or income generated from the Israeli market.^{24, 25}

Disclosed NHS England commercial revenue generated in Israel: no public evidence identified.

Profit repatriation

NHS England operates within the UK statutory healthcare funding framework and publishes annual public accounts.^{9, 22}

An Israeli parent company receiving NHS England dividends, a private shareholder profit distribution, or profits from Israeli NHS England operations remitted to the United Kingdom: no public evidence identified.

Supplier payments and onward flows

The original national Federated Data Platform contract had a reported maximum potential value of £330 million over a seven-year period.¹

This reported maximum contract value does not establish the amount invoiced or paid by NHS England, or the ultimate geographic destination of the supplier’s expenditure.¹

Palantir’s 2024 Form 10-K independently confirms an Israeli defence partnership but does not identify NHS England contract receipts as its source of financing.²

A quantified NHS England payment to an Israeli defence entity, Israeli government agency, or settlement-based enterprise: no public evidence identified.

Contribution through contractor relationships

The documented NHS England–Palantir procurement establishes a commercial relationship with a multinational technology supplier whose wider corporate group separately maintains an Israeli defence partnership.^{1, 2}

The available public records do not establish that NHS England directly financed, operated, or controlled that defence partnership.^{1, 2}

Economic significance within Israel

An Israeli government designation identifying NHS England as a major domestic employer, Israeli technology-sector investor, healthcare infrastructure provider, settlement investor, or Israeli national-market participant: no public evidence identified.

Israeli sovereign financing

NHS England purchases of Israel Bonds, Israeli sovereign debt underwriting, lending to Israeli banks, financing of settlement development, or investment in Israeli defence manufacturers: no public evidence identified.

Temporal record

NHS England’s Federated Data Platform procurement was awarded in November 2023, before the July 2024 and November 2024 chronology thresholds.¹

Palantir disclosed an Israeli defence partnership agreed during 2024.²

Manchester City Council documented NHS operational use and public scrutiny of the Federated Data Platform during September 2026, confirming that the programme remained relevant after both chronology thresholds.¹

Whether any identifiable portion of payments under the NHS England contract subsequently financed Israeli defence activities: no public evidence identified.